MRK

Merck & Company, Inc. NYQ · MRK

$127.50 -0.13 (-0.10%)

Neutral · +0.96σ Grade B

+ Compare Open in Sniper

Mkt cap $314.9B

P/E 36.0

Day $127.03 – $131.74

52wk $106.03 – $131.74

Avg vol 10.3M

Beta 0.20

Div yld 2.67%

Next earnings 2026-08-04

Quick read

Plain English

Merck & Co., Inc. operates as a healthcare company worldwide.

MRK last traded at $127.50, down 0.1% on the day; that's in the upper part of its 52-week range ($106.03–$131.74). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-08-04) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC2 upper, +0.96 ATR from EMA21 — shooting star

Long —

score 12 · tech 12 / 80 · support 0 / 20

above KC1 lower, +0.96 ATR from EMA21 · no notable pattern

· Aligned with weak uptrend

How this grade was earned

total 12 pts

Cycle position 6

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short B

score 46 · tech 46 / 80 · support 0 / 20

KC2 upper, +0.96 ATR from EMA21 · shooting star

ℹ️ Stretched (KC2): stop is set a little wider to avoid a whipsaw, so the reward/risk reads a bit lower by design.

· KC2 upper stretch — standard mean-reversion tier
· Shooting star — long upper wick rejection
· RSI hook from overbought (58)

How this grade was earned

total 46 pts

Cycle position 22

Candle signal 15

Momentum 6

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Candle-size grades

tap a size to open that chart

15mC30m–1h–4h–1DB

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 58), the trend is quiet (ADX 17), and volume is about normal (1.2×). On the business side, revenue is growing 5% year over year and the business keeps about 22 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI

0–100 · <30 oversold

Trend strength · ADX

>25 = strong trend

Volume vs avg

1.18×

1× = average

Stretch from avg

+1.0 ATR

− below · + above

Zone touches

tests of this zone

Suggested hold

3–30

bars (≈ days)

Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth

+4.9%

year over year

Free-cash-flow margin

21.6%

cash kept per $ of sales

Debt / equity

1.07

lower = less leveraged

P/E ratio

35.9

price ÷ yearly profit

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $81.70 (fair range $64–$126); today's price sits 56% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$81.70

Fair-value range

$63.90 – $125.83

Margin of safety

-56%

Verdict

Overvalued

Accounting quality Weak

✓ Positive retained earnings
✓ Gross margin 77% (pricing power)

⚠ Debt exceeds cash
⚠ Quick ratio 0.62 (fragile)
⚠ Receivables growing faster than revenue
⚠ Inventory growing faster than revenue

Price implies ~11% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

MRK is a $314.9 billion company, priced at 36× last year's earnings, and it moves more calmly than the market (beta 0.2).

Mkt cap $314.9B

P/E ttm 36.0

Fwd P/E 13.2

Beta 0.20

Day range $127.03 – $131.74

52w range $106.03 – $131.74

Avg vol 10.3M

RSI(2) 81.5

ROE 18.9%

Net mgn 13.6%

FCF mgn 21.4%

Debt/Eq 1.07

Div yld 2.67%

Sector Healthcare

Industry Drug Manufacturers - General

Next earn 2026-08-04

52-week range · today's price

$106.03$131.74

More on MRK

Options idea

See more →

CALL $125 2026-08-21

$6.82

ITM PUT $135 2026-09-18 · 62d

~$10.67

OTM PUT $120 2026-09-18 · 62d

~$2.98

ITM tracks the stock · OTM is cheaper / more leverage. Model-priced — verify the live chain. As of 10h ago (2026-07-18 18:02 UTC).

Earnings

See more →

Last reported: 2026-04-30
EPS (act / est): -1.28 / -1.47
Surprise: +13.2%
Next report: 2026-08-04

About

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, B…